Target Information

Target General Information

Top

Target ID

T65755 (Former ID: TTDC00297)

Target Name

Histone deacetylase (HDAC)

Synonyms

Human histone deacetylase

Click to Show/Hide

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 2 Target-related Diseases

Epilepsy/seizure [ICD-11: 8A61-8A6Z]

Muscular atrophy [ICD-11: 8B61]

Function

Responsible for the deacetylation of lysine residues on the n-terminal part of the core histones (H2a, H2b, H3 and H4). Histone deacetylation givesa tag for epigenetic repression and plays an important role in transcriptional regulation.

Click to Show/Hide

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 3 Approved Drugs

Sodium phenylbutyrate

Drug Info

Approved

Spinal muscular atrophy

[2]

Valproate

Drug Info

Approved

Epilepsy

[3], [4], [5]

HBI-8000

Drug Info

Registered

Solid tumour/cancer

[6], [7]

Clinical Trial Drug(s)

[+] 26 Clinical Trial Drugs

Abexinostat

Drug Info

Phase 3

Follicular lymphoma

[8]

CMS-024-02

Drug Info

Phase 3

Solid tumour/cancer

[9]

ITF2357

Drug Info

Phase 3

Duchenne dystrophy

[10]

NVP-LAQ824

Drug Info

Phase 3

Mood disorder

[11]

Pracinostat

Drug Info

Phase 3

Acute myeloid leukaemia

[12], [8]

SNDX-275

Drug Info

Phase 3

Breast cancer

[13]

APH-0812

Drug Info

Phase 2

Human immunodeficiency virus-1 infection

[14], [15]

DAC-060

Drug Info

Phase 2

Keratosis

[16]

JNJ-26481585

Drug Info

Phase 2

Advanced stage follicular lymphoma

[17]

MGCD-0103

Drug Info

Phase 2

Solid tumour/cancer

[18], [19]

PDX-101

Drug Info

Phase 2

Solid tumour/cancer

[20]

Remetinostat

Drug Info

Phase 2

Basal cell carcinoma

[21]

Rocilinostat

Drug Info

Phase 2

Multiple myeloma

[22]

SHAPE

Drug Info

Phase 2

Cutaneous T-cell lymphoma

[12]

CUDC-907

Drug Info

Phase 1/2

Acute myelogenous leukaemia

[23]

EDO-S101

Drug Info

Phase 1/2

Solid tumour/cancer

[8]

Tinostamustine

Drug Info

Phase 1/2

Multiple myeloma

[24]

Tractinostat

Drug Info

Phase 1/2

Lymphoma

[8]

CG-200745

Drug Info

Phase 1

Solid tumour/cancer

[25]

CT-200

Drug Info

Phase 1

Solid tumour/cancer

[26]

CXD-101

Drug Info

Phase 1

Solid tumour/cancer

[27]

GSK311739

Drug Info

Phase 1

Rhinovirus infection

[28]

GSK3117391

Drug Info

Phase 1

Rheumatoid arthritis

[29]

OBP-801

Drug Info

Phase 1

Solid tumour/cancer

[30]

OKI 179

Drug Info

Phase 1

Solid tumour/cancer

[31]

VTR-297

Drug Info

Phase 1

Hematologic tumour

[32]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

CS-00028

Drug Info

Preclinical

Solid tumour/cancer

[33]

Discontinued Drug(s)

[+] 1 Discontinued Drugs

MKC-1313

Drug Info

Terminated

Solid tumour/cancer

[34]

Mode of Action

[+] 3 Modes of Action

Inhibitor

[+] 128 Inhibitor drugs

Sodium phenylbutyrate

Drug Info

[4], [35]

Valproate

Drug Info

[1], [36], [37], [38], [39]

HBI-8000

Drug Info

[8], [21]

ITF2357

Drug Info

[10]

NVP-LAQ824

Drug Info

[42]

SNDX-275

Drug Info

[8], [21]

APH-0812

Drug Info

[14], [15]

DAC-060

Drug Info

[44]

MGCD-0103

Drug Info

[8]

Remetinostat

Drug Info

[8], [21]

Rocilinostat

Drug Info

[47]

SHAPE

Drug Info

[48]

CUDC-907

Drug Info

[8], [10]

EDO-S101

Drug Info

[8]

Tinostamustine

Drug Info

[49]

Tractinostat

Drug Info

[8]

CG-200745

Drug Info

[50]

CT-200

Drug Info

[51]

CXD-101

Drug Info

[52]

OBP-801

Drug Info

[8]

OKI 179

Drug Info

[55]

VTR-297

Drug Info

[56]

Ampicidin analog 1

Drug Info

[57]

Ampicidin analog 2

Drug Info

[57]

Aniline derivative 1

Drug Info

[58]

Indole-based analog 11

Drug Info

[58]

Oxazolyl methylthiothiazole derivative 1

Drug Info

[58]

PMID27376512-Compound-PG-11047

Drug Info

[59]

PMID27376512-Compound-PG-11048

Drug Info

[59]

PMID28092474-Compound-32

Drug Info

[60]

PMID28092474-Compound-33

Drug Info

[60]

PMID28092474-Compound-34

Drug Info

[60]

PMID29671355-Compound-53

Drug Info

[61]

PMID29671355-Compound-69

Drug Info

[61]

MKC-1313

Drug Info

[63]

(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one

Drug Info

[64]

2,2-bis(3-fluorophenyl)-N-hydroxyacetamide

Drug Info

[65]

2,2-bis(4-chlorophenyl)-N-hydroxyacetamide

Drug Info

[65]

2,2-bis(4-fluorophenyl)-N-hydroxyacetamide

Drug Info

[65]

2-(methylsulfonylthio)ethyl 2-propylpentanoate

Drug Info

[66]

4-Benzoylamino-N-hydroxy-benzamide

Drug Info

[67]

4-Butyrylamino-N-hydroxy-benzamide

Drug Info

[68]

4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide

Drug Info

[69]

4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide

Drug Info

[70]

4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide

Drug Info

[69]

4-Phenylbutyrohydroxamic acid

Drug Info

[71]

5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide

Drug Info

[72]

5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione

Drug Info

[66]

5-Mercapto-pentanoic acid phenylamide

Drug Info

[70]

6-(2-Bromo-acetylamino)-hexanoic acid phenylamide

Drug Info

[70]

6-benzenesulfinylhexanoic acid hydroxamide

Drug Info

[73]

6-benzenesulfonylhexanoic acid hydroxamide

Drug Info

[73]

6-Mercapto-hexanoic acid phenylamide

Drug Info

[70]

6-Phenoxy-hexane-1-thiol

Drug Info

[70]

6-phenylsulfanylhexanoic acid hydroxamide

Drug Info

[73]

7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one

Drug Info

[64]

7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one

Drug Info

[74]

7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one

Drug Info

[64]

7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one

Drug Info

[64]

7-Mercapto-heptanoic acid benzothiazol-2-ylamide

Drug Info

[70]

7-Mercapto-heptanoic acid biphenyl-3-ylamide

Drug Info

[70]

7-Mercapto-heptanoic acid biphenyl-4-ylamide

Drug Info

[70]

7-Mercapto-heptanoic acid phenylamide

Drug Info

[70]

7-Mercapto-heptanoic acid pyridin-3-ylamide

Drug Info

[70]

7-Mercapto-heptanoic acid quinolin-3-ylamide

Drug Info

[70]

8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one

Drug Info

[64]

8-Mercapto-octanoic acid phenylamide

Drug Info

[70]

8-Oxo-8-phenyl-octanoic acid

Drug Info

[69]

8-Oxo-8-phenyl-octanoic acid hydroxyamide

Drug Info

[74]

9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide

Drug Info

[74]

9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one

Drug Info

[74]

Apicidin

Drug Info

[75], [38], [76]

Azelaic bishydroxamic acid

Drug Info

[38]

CG-1521

Drug Info

[38]

CHAP1

Drug Info

[75], [77]

CHAP31

Drug Info

[75], [77]

Cyclostellettamine derivative

Drug Info

[78]

N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide

Drug Info

[80]

N-(2-aminophenyl)-4-methoxybenzamide

Drug Info

[81]

N-(2-aminophenyl)nicotinamide

Drug Info

[80]

N-(2-Ethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide

Drug Info

[82]

N-(2-Mercapto-ethyl)-N'-phenyl-succinamide

Drug Info

[82]

N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(3-Ethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(4-aminobiphenyl-3-yl)nicotinamide

Drug Info

[80]

N-(4-Ethylphenyl)-N'-hydroxyoctanediamide

Drug Info

[79]

N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide

Drug Info

[83]

N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide

Drug Info

[69]

N-(5-Hydroxycarbamoyl-pentyl)-benzamide

Drug Info

[83]

N-(6-Hydroxycarbamoyl-hexyl)-benzamide

Drug Info

[69]

N-(6-Mercapto-hexyl)-benzamide

Drug Info

[70]

N-hydroxy-2,2-diphenylacetamide

Drug Info

[65]

N-hydroxy-2,2-diphenylpropanamide

Drug Info

[65]

100

N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide

Drug Info

[67]

101

N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide

Drug Info

[67]

102

N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide

Drug Info

[67]

103

N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide

Drug Info

[67]

104

N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide

Drug Info

[67]

105

N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide

Drug Info

[67]

106

N-Hydroxy-4-(pentanoylamino-methyl)-benzamide

Drug Info

[68]

107

N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide

Drug Info

[68]

108

N-Hydroxy-4-phenylacetylamino-benzamide

Drug Info

[67]

109

N-hydroxy-9,10-dihydroanthracene-9-carboxamide

Drug Info

[65]

110

N-hydroxy-9H-xanthene-9-carboxamide

Drug Info

[65]

111

N-Hydroxy-N'-(2-methylphenyl)octanediamide

Drug Info

[79]

112

N-Hydroxy-N'-(3-methylphenyl)octanediamide

Drug Info

[79]

113

N-Hydroxy-N'-(4-methoxyphenyl)octanediamide

Drug Info

[79]

114

N-Hydroxy-N'-(4-methylphenyl)octanediamide

Drug Info

[79]

115

N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide

Drug Info

[84]

116

Octanedioic acid bis-hydroxyamide

Drug Info

[71]

117

Octanedioic acid hydroxyamide pyridin-2-ylamide

Drug Info

[69]

118

Octanedioic acid hydroxyamide pyridin-4-ylamide

Drug Info

[69]

119

PSAMMAPLIN A

Drug Info

[74]

120

ST-2986

Drug Info

[85]

121

ST-2987

Drug Info

[85]

122

ST-3050

Drug Info

[85]

123

ST-5732

Drug Info

[86]

124

Suberic bishydroxamic acid

Drug Info

[38]

125

Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester

Drug Info

[70]

126

Trapoxin

Drug Info

[77]

127

Trichostatin A

Drug Info

[37], [75], [87]

128

Trifluoromethylketone

Drug Info

[38]

Modulator

[+] 7 Modulator drugs

Abexinostat

Drug Info

[40]

CMS-024-02

Drug Info

[41]

Pracinostat

Drug Info

[43]

JNJ-26481585

Drug Info

[45]

PDX-101

Drug Info

[46]

GSK311739

Drug Info

[53]

GSK3117391

Drug Info

[54]

Antagonist

[+] 1 Antagonist drugs

CS-00028

Drug Info

[62]

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

References

Top

REF 1

Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.

REF 2

ClinicalTrials.gov (NCT00533559) Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl. U.S. National Institutes of Health.

REF 3

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7009).

REF 4

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 5

Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.

REF 6

REF 7

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025931)

REF 8

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 9

ClinicalTrials.gov (NCT01489566) Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients. U.S. National Institutes of Health.

REF 10

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 11

Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.

REF 12

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 13

ClinicalTrials.gov (NCT03538171) Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer. U.S. National Institutes of Health.

REF 14

Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.

REF 15

Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36.

REF 16

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031213)

REF 17

ClinicalTrials.gov (NCT01486277) A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

REF 18

REF 19

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008 Apr;7(4):759-68.

REF 20

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.

REF 21

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 22

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032606)

REF 23

ClinicalTrials.gov (NCT04278768) Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS. U.S. National Institutes of Health.

REF 24

ClinicalTrials.gov (NCT03687125) Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1). U.S.National Institutes of Health.

REF 25

ClinicalTrials.gov (NCT01226407) Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile. U.S. National Institutes of Health.

REF 26

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027375)

REF 27

ClinicalTrials.gov (NCT01977638) Phase 1 Trial of CXD101 in Patients With Advanced Cancer. U.S. National Institutes of Health.

REF 28

Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.

REF 29

Clinical pipeline report, company report or official report of GlaxoSmithKline.

REF 30

ClinicalTrials.gov (NCT02414516) A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.

REF 31

ClinicalTrials.gov (NCT03931681) A Study of OKI-179 in Patients With Solid Tumors. U.S. National Institutes of Health.

REF 32

ClinicalTrials.gov (NCT03838926) Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies. U.S. National Institutes of Health.

REF 33

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021167)

REF 34

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024821)

REF 35

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.

REF 36

Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009 Sep;297(3):F729-39.

REF 37

Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15.

REF 38

Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.

REF 39

The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-50.

REF 40

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.

REF 41

US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.

REF 42

Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.

REF 43

REF 44

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369.

REF 45

REF 46

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

REF 47

National Cancer Institute Drug Dictionary (drug id 698408).

REF 48

Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.

REF 49

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018 Feb 27;11(1):32.

REF 50

Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379.

REF 51

Clinical pipeline report, company report or official report of Celleron.

REF 52

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7.

REF 53

Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014.

REF 54

The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42.

REF 55

Clinical pipeline report, company report or official report of OnKure Therapeutics.

REF 56

Clinical pipeline report, company report or official report of Vanda Pharmaceuticals.

REF 57

Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30.

REF 58

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.

REF 59

DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.

REF 60

Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.

REF 61

HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.

REF 62

US patent application no. 2009,0162,329, Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure.

REF 63

ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005.

REF 64

Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.

REF 65

Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.

REF 66

New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.

REF 67

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.

REF 68

Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.

REF 69

Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.

REF 70

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.

REF 71

Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.

REF 72

Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.

REF 73

Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.

REF 74

Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.

REF 75

Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.

REF 76

Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells. Cancer Lett. 2003 Jan 28;189(2):197-206.

REF 77

Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6.

REF 78

Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.

REF 79

Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.

REF 80

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

REF 81

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.

REF 82

Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.

REF 83

Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79.

REF 84

Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.

REF 85

N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.

REF 86

Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3.

REF 87

Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 2003 May 1;101(9):3451-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN